INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA):IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

An Introduction To Pharmaceutical Excipients Use In Soid Oral Formulation : A Review

Rajeshwari G. Khairanar , Aniket T. Chavan*, Rupali R. Tasgaokar

Tadavrao Tasgaonkar Institute Of Pharmacy, Bhivpuri Road, Karjat

ARTICLE INFO

Received: 29 March 2024
Accepted: 02 April 2024
Published: 03 April 2024
Keywords:
excipients , interaction , co-processed excipients,standardization
DOI:
10.5281/zenodo.10912711

ABSTRACT

Excipients play an important part in formulating a lozenge form. These are the constituents which along with Active Pharmaceutical constituents make up the lozenge forms. Excipients act as defensive agents, bulking agents and can also be used to ameliorate bioavailability of medicines in some cases, the following review discusses the colorful types and sources of excipients along with their uses, and these can be used for different conditioning. Some excipient relations can be mischievous and need to be avoided. This has been detailed out in the commerce section. Excipients as like other active pharmaceutical constituents need to be stabilized and formalized; the following review gives brief information about standardization and stabilization process along with the safety evaluation parameters of the excipients

INTRODUCTION

Excipients in medicinals are substances other than the pharmacologically active medicine or active constituents that are included in the manufacturing process or are contained in a finished pharmaceutical product lozenge form. The excipient has numerous functions in the form of a pharmaceutical medication, including solubility modulation & API bioavailability, enhancing the stability of active component in the lozenge forms, helping the active component maintains preferred polymorphic forms or conformations, disintegrant, lubricant, binder, and filler. In opting pharmaceutical excipients, dosag forms and medicine products the excipient must have a standard to assure the harmonious quality and functioning of the excipient. In the solid lozenge form, the medicine is in intimate contact with one or further excipient; the ultimate may affect the stability of the medicine. Knowledge of medicine excipient commerce is veritably useful for inventors in choosing the right excipients. This information may formerly live for given medicines(Patel etal., 2011).

Need for new Excipients:-

Excipients help in maintaining a good safety and stability profile of the medicine product. The development of new excipients has been request-

***Corresponding Author:** Aniket T. Chavan
Address: *Tadavrao Tasgaonkar Institute of Pharmacy, Bhivpuri road, Karjat*
Email : aniketchavan2282@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

driven over the times with an ever- adding demand for excipients with bettered physicochemical and stability parcels. thus, there is growing pressure on the hunt for new excipients that will enhance the overall stability and parcels of the expression

Types of Insecurity Excipients :-

may be affected by chemical, physical, or microbiological insecurity. Physical insecurity involves phase metamorphosis of the excipients, which may be due to polymorphic changes, hydration and dehumidification, rush, or changes in the unformed or liquid nature. The phase metamorphosis can do via aggregation, coagulation, melting, or detergent- intermediated mechanisms(solubility). Thermal stresses during manufacturing processes similar as milling, dry granulation, and contraction could beget these phase metamorphoses. Physical changes in the excipient during manufacturing and storehouse can master its purpose of selection . Chemical insecurity may do owing to thermolytic, oxidative, or photolytic declination. Hydrolysis, a type of thermolytic declination, and oxidation, which is generally intermediated by peroxides, are the major causes of excipient declination. Oxidative declination may also do via transition essence- intermediated electron transfer or by autoxidation, which involves free revolutionary-initiated chain responses. Excipients also have the tendency to absorb light and therefore degrade photolytically and their reactivity is frequently advanced in the agitated energy countries(3,5). Microbiological insecurity would be a result of failure of preservative in the expression due to commerce, declination, or loss from the system. Solid Oral Lozenge Forms The oral route is the most patient- biddable and conventional route of medicine administration. specifics similar as tablets, capsules, capsules, and solid maquillages can be administered orally to achieve the asked remedial goods. These specifics are generally formulated with or witho of scaling- up, and brittle fracture propensity. DCPD has a high stoichiometric water content of20.9(w/ w), and as a diluent, it can constitute over 50(w/ w) of the capsule form. The dehydration behavior of DCPD is unusual as it's accelerated in the presence of water vapor and hindered under dry conditions. The dehydration of a small bit of DCPD can release sufficient water to beget physical and chemical changes in the expression. An important aspect of DCPD dehydration is that it's delicate and not generally apparent to descry the in situ release of water. Further, the water, if liberated, is readily taken up by one or farther factors in the expression. Lactose(β- d- galactopyranosyl(1- 4)- d- glucopyranose) is a regularly used accretive in the medicinal and food industriousness. It has a strong tendency to solidify from its unformed form when stored at high relative humidity. Lactose shows incompatibility with strong oxidizers. Anhydrous lactose has been set up to mount in the declination of drugs with ester and amidine groups via hydrolysis. Under high humidity conditions, lactose, which is a reducing sugar, has the tendency to interact with primary and secondary amines(Maillard response). unformed lactose has a truly low moisture content after spray- drying and exhibits hygroscopicity. The crystallization of lactose occurs with the increase in water content during storage over time, which leads to riming and cementing of the cream. Further, release of reprised fat has been observed when lactose crystallizes from maquillages of spray- dried sodium caseinate/ lactose mixes having an oil painting oil phase. Lactose shows incompatibility with aceclofenac, ketoprofen, lisinopril, and oxprenolol. Sorbitol in bulk form is hygroscopic, hence taking storage in a cool and dry place. In strongly acidic or introductory media, sorbitol reacts with divalent and trivalent substance ions to form water-answerable chelates. It forms a waxy, water-answerable gel with polyethylene glycol.

Types of Diluents:-

Microcrystalline Cellulose MCC is a purified, incompletely depolymerized cellulose deduced from α- cellulose. MCC is a protean excipient with operation as a diluent, binder, and disintegrant in oral solid lozenge forms. It's primarily used as a diluent/ binder in direct contraction and wet granulation process. As a diluent, it's used in tablet phrasings in the range of 20 – 90 w/w. MCC undergoes plastic distortion and shows good compactability indeed at low contraction pressures. still, it has poor inflow characteristics. It's available in different flyspeck sizes and consistence, with larger flyspeck size and advanced bulk viscosity helping in the inflow characteristics of composites but at the cost of reduced DILUENTS/ paddings 53 compactability. In direct contraction process, it's frequently used with other excipients due to its comparatively high cost. In dry granulation, MCC is frequently combined with a diluent similar as lactose with brittle contraction property to round the plastic distortion geste of MCC. Wet granulation has been known to reduce the compactability of MCC due to change in structure and loss of relating shells 8 – 10). Being hygroscopic in nature, it's important to control the humidity content in MCC especially for humidity-sensitive medicine substances. From a manufacturability perspective, having optimum humidity is helpful ago low and high humidity may concession compactability. Due to the capability of MCC to suffer plastic distortion, it's sensitive to magnesium stearate, with finer size bit being more sensitive to lubricant and mixing goods. Blending colloidal silica with MCC previous to lubrication has been known to reduce magnesium stearate perceptivity of MCC due to preferential list of colloidal silica to magnesium stearate. In addition, being a plastically screwing material, tabletability of MCC is also negatively impacted with adding tablet press pets due to time-dependent nature of plastic inflow. A popular system for prostrating some of the undesirable parcels of MCC bandied then's through coprocessing with other excipients. Coprocessing is compactly bandied at the end of this chapter. A recent further comprehensive review on MCC has been published by Thoorens etal.

Dibasic Calcium Phosphate:-

Anhydrous and dihydrated forms of dibasic calcium phosphate(DCP) are used as paddings for oral solid capsule forms. It's farther generally used as a source of calcium in nutraceuticals than in the pharmaceutical sedulity. The popularity of DCP in the pharmaceutical sedulity is due to its excellent flux and compression In addition, due to advanced intraparticular porosity, corruption of anhydrous DCP is better than the dihydrate form. still, both forms of DCP do not induce good corruption force and needs a lump- type disintegrant in the expression when used. Different grades of DCP are available, with coarse grade used for direct compression and mulled grade for roller compression or wet granulation. The mulled grade has an alkaline pH and can't be used with API inharmonious with high pH. Being an inorganic tar, DCP can be abrasive on the tablet tooling. still, compared to MCC, it's less sensitive to magnesium stearate situations.

Excipients Added to Solid Oral Lozenge Forms to Improve Drug Solubility and/ or Dissolution

Excipients that Form Addition Complexes with medicine motes The term ‘ complex conformation ’ or ‘ complexation ’ refers to the list of two or further individual motes to form a concerted chemical product, which act as a single chemical unit. One of the most constantly employed complexation responses in pharmaceutical lores is complexation of medicine motes with cyclodextrin motes. Cyclodextrin is developed through an enzymatic response with bounce to form a crystalline andnon-hygroscopic cone- shaped patch that has ideal parcels for

complexation with certain API motes. Cyclodextrin motes form addition complexes with hydrophobic,non-polar motes by accommodating them in the hydrophobic depression of the cone. Cyclodextrins(CDs) are characterized by a toroidal shape with a lipophilic center and a hydrophilic external face. There are three natural cyclodextrins, videlicet α-cyclodextrin(αCD), β- cyclodextrin (βCD) and γ-cyclodextrin(γCD), which have six, seven and eight glucose units, independently. The most frequent operation of forming addition complexes between cyclodextrin and an API is to increase the apparent waterless solubility of the API(specifically those belonging to BSC class II and IV). Other operations of complex conformation include enhancement of medicine stability, minimization of adverse medicine goods or side-goods and enhancement of organoleptic parcels similar as taste and smell. It's important to note, still, that not all addition complex conformations always give an increase in API solubility and/ or immersion. Pharmaceutics 2020, 12, 393 4 of 17 Cyclodextrins have been extensively employed as solubility and dissolution modifying excipients in colorful oral lozenge forms. These lozenge forms include conventional immediate release tablets, orally disintegrating tablets, bouncy tablets, and modified release lozenge forms including slow release or sustained release medicine delivery systems(18 – 20). Cyclodextrins are frequently preferred over organic detergents as a means to enhance solubility and dissolution due to their safety and because they are well permitted. In addition, advances in inheritable engineering, technology and process inventions led to the product of αCD, βCD as well as γCD as pharmaceutical excipients on economically and commercially respectable scales. still, due to the fairly low solubility as well as nephrotoxicity of βCD, it isn't suitable for parenteral administration. Accordingly, further answerable and less poisonous cyclodextrin derivations have been developed, which include hydroxypropyl- β-cyclodextrin(HP- β- CD) and sulfobutylether- β-cyclodextrin(SBE- β- CD). exemplifications of the salutary goods of cyclodextrins as functional excipients on APIs are stressed by Conceição etal., which include the increased solubility of carbamazepine by means of complexation with HP- β- CD. The effect of complexation of carbamazepine with HP- β- CD is farther illustrated by a study conducted by Kou etal. A complex of HP- β- CD with carbamazepine was prepared in the presence of0.1 hydroxypropyl methyl cellulose(HPMC). The formed complex had increased the solubility of carbamazepine up to 95 times when compared to the medicine alone. likewise, the complexation of carbamazepine with HP- β- CD rendered a1.5-fold increase in the bioavailability of carbamazepine in beagle tykes when compared with an immediate- release commercially available carbamazepine tablet. The HP- β- CD- containing expression rendered a maximum tube attention(Cmax) of4951.04 ±1585.21 ng/ mL and area under the wind(AUC0 – ∞) of8597.85 ±2786.18 ng · h/ mL in comparison to a Cmax of3577.99 ±1444.90 ng/ mL and AUC0 – ∞ of6000.65 ±2227.61 ng · h/ mL for the commercially available expression. The enhancement in bioavailability was attributed to an increase in dissolution rate of the HP- β- cyclodextrin complex containing expression. In a study by Desai etal.(21), orally disintegrating tablets(ODTs) were prepared containing an addition complex between eslicarbazepine and β- CD, which was prepared by using a solid dissipation fashion. The ODT expression displayed 100 dissolution within 60 min compared to 72 dissolution for a commercially available tablet expression. In an in vivo study in rabbits, the ODT expression displayed an advanced bioavailability in comparison to the commercially available

expression as characterized by a Tmax of 2 h, Cmax of6661.34 ng/ mL and AUC0 – ∞ of 49,887.9 ng/ mL · h in comparison to a Tmax of 4 h, Cmax of2534.39 ng/ mL and AUC0 – ∞ of 23,684.7 ng/ mL · h for the marketable expression.

The ideal characteristics of an excipient are given as under:-

An excipient must be:-

- Chemically stable
- Non reactive
- Low equipment and process sensitive
- Inert to human body
- Non toxic
- Acceptable with regards to organoleptic
- characteristics
- Economical
- Having efficiency in regards with the intended use.

Excipients even though considered inert substance,

Classification of excipients based on their functions 10-13:-

Excipients are classified on the base of the functions they perform similar as- colorful excipients used in solid lozenge forms perform colorful functions like- Binders, diluents, lubricants, disintegrating agent's plasticizers etc,e.g. when 5 bounce is used in expression it acts as a binder for tablet phrasings where as when it's used in dry form it can perform the function of a disintegrant. Excipients that are used in liquid lozenge forms are- Detergents co-detergents, buffersanti-microbial agents emulsifying agents enhancing agents, flavors, etc Some excipients have remedial values which are classified as under- Anesthetics 10- chloroform, etc Laxatives- bentonite, psyllium, xanthan gum1

CONCLUSION:-

Meanwhile pharmaceutical industriousness have recognized their eventuality for delivering medicinal products and have launched several products for the OTC request using this technology. The fast dissolving thin film are hardly described and excavated in literature, but feel to be an ideal capsule form for use in immature children, especially in elderly and pediatric cases. They combine the lower stability of a solid capsule form and the good connection of a liquid. Due to lack of standard methodology for drug and analysis products actuality in the request is limited. Isosorbide mononitrate is not available as patient compliance orally disintegrating dosage form. Thus present attempt of developing Isosorbide mononitrate oral thin film was successful and the developed Isosorbide mononitrate oral thin film is a viable alternative for Isosorbide mononitrate immediate release tablets. dosage form is convenient for the geriatric patients and bedridden patients are unwilling to take solid do solid dosage form.

REFERENCE

1. Patel, J.; Patel, K.R.; Patel, N.M.Review on fast dissolving film.Int. J.Univers. Pharm. Bio. Sci., 2013, 2(1), 149-162.
2. Guidance for Industry Orally Disintegrating Tablets. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070578.pdf. (Accessed March 4,2013).
3. CENTER FOR DRUG EVALUATION AND RESEARCH. CMC review.http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022524Orig1s000ChemR.pdf. (Accessed March 4, 2013).
4. Dhere, P.M.; Patwekar, S.L. Review on preparation and evaluation of oral disintegrating films.Int. J. Pharm. Tech.,2011, 3(4), 1572-1585.
5. Zhang, H.; Zhang, J.; Streisand, J.B. Oral mucosal drug delivery: Clinical pharmacokinetics and therapeutic

applications. Clinical Pharmacokinetics.2002, 41, 661-680.
6. Dixit, R.P.; Puthli, S.P. Oral strip technology overview and future potential. J. Controlled. Release, 2009, 139, 94-107.
7. Siddiqui,M.D.N.; Garg, G.; Sharma, P.K. A short review on "A novel approach in oral fast dissolvingdrug delivery system and their patents".Adv. Biol. Res.,2011,5(6), 291-303.
8. Thin film technology. file:///G:/Oral films/Dissolvable films and ODT/dissol films.htm.(Accessed June 28, 2012).
9. Kalyan, S.; Bansal, M. Recent trends in the development of oraldissolving film.Int.J. Pharm. Tech. Res., 2012,4(2), 725-733.
10. Lou, H.; Liu, M.; Qu, W.; Hu, Z.; Brunson, E.; Johnson, J.; Almoazen, H.Evaluation of Chlorpheniramine Maleate microparticles in orally disintegrating film and orally disintegrating tablet for pediatrics.Drug Dev. Ind. Pharm. 2013.
11. Sievens-Figueroa,L.; Bhakaya, A.; Jerez-Rozo, J.I.; Pandya, N. Roma˜nachb, R.J.; Michniak-Kohnd, B.; Iqbal, Z.; Bilgili, E.; Dave, R.N. Preparation and characterization of hydroxypropyl methyl cellulose filmscontaining stable BCS Class II drug nanoparticles for pharmaceutical applications.Int. J. Pharm., 2012, 423, 496-508.
12. Roche, E.J.; Freeman, E.M.; Papile, S.M. Taste mask coatings for preparing chewable pharmaceutical tablets. European Patent Application. EP0538034,April 21, 1993
13. Andou, Y.; Hayata, K.; Mitake, K.; Takahashi, I.;Yamaga, H. Easily swallowablejelly like preparation containing Terfenadine. Japanese Patent, 10,007,565, January 13, 1998.
14. Motola, S.; Agisim, G.R.; Mogavero, A. Palatable Ibuprofen solutions. U.S. Patent 5,024,997, June 18, 1991.
15. Farmvita.net. Licensing and regulatory network.http://www.farmavita.net/content/view/862/96/ (Accessed June 28, 2012).
16. Ozer, A.Y.; Hincal. A.A. Studies on the masking of unpleasant tast of Beclamide: Microcapsulation and tableting.J.Microencapsul.,1990, 7(3), 327-339.
17. Jain, N.K. Advances in controlled and novel drug delivery, 1st ed.;2001, pp. 290-306.
18. Kasturagi, Y.; Sagiura, Y.C.; Lee, K.; Otsugi; Kurihara. Selective inhibition of bitter taste of various drugs by lipoprotein.Pharm. Res., 1995, 12(5), 658-662.
19. Corniello, C. Quick dissolving strips: From concept to commercialization. Drug Delivery Technol.,2006, 6, 68 -71.
20. Nagar, P.; Chauhan, I.; Yasir, M. Insights into polymers: Film Formers in mouth dissolving films. Drug Invention Today, 2011, 3(12), 280-289.
21. Gomez-Guillen, M.C.; Turnay, J.; Fernandez-Martin, F.;Ulmo, N.; Lizarbe, M.A.; Montero, P. Food hydrocolloid. 2002, 16, 25-34.
22. Bourtoom, T.Edible films and coatings: characteristics and properties.Int. Food Res. J., 2008, 15(3), 1-15.
23. Sobral, P.J.A.; Habitante, A.M.Q.B. Food hydrocolloid. 2001, 15, 377-382.
24. Ghorwade, V.; Patil, A.; Patil, S.; Ikkurthi,K.; Inuganti, K.S.; Porandla, V.Formulation and evaluation of Montelukast sodium fast dissolving films by using gelatin as a film base. Res. J. Pharm. Biol. Chem. Sci.,2011, 2(3), 880-888.
25. Leduy, A.; Zajic, J.E.; Luong, J.H.T. Pullulan In: Encyclopedia Of polymer science and engineering, 2nd ed., Wiley & Sons,New York, 1988.
26. Conca, K.R.; Yang, T.C.S. Edible food barrier coatings. In: Biodegradable polymers and packaging, Ching, C.; Kaplan, D.L.; Thomas,

& E.L., Eds., Technomic Publishing Company, Inc., 1993, pp. 357-369.
27. U.S. Congress, Office of Technology Assessment, Biopolymers: Making materials nature's way-Background paper, OTA-BP-E-102 Washington, DC: U.S. Government Printing Office, 1993.
28. Foss, C.D.; Hoffman, A.; Shen, S.; Stucky, A.M.; Turner, J.L. Edible Pullulan Films Containing Flavoring. U.S. Patent Application, 0011115 A1, January 8, 2009.
29. Saini, S.; Samta, A,C.; Rana, G.S. Optimization of formulation of fast dissolving films made of pullulan polymer. Int. J. Pharm. Sci. Rev. Res., 2011, 9(1), 127-131

HOW TO CITE: Rajeshwari Khairanar , Aniket T. Chavan, Rupali R. Tasgaokar, An Introduction To Pharmaceutical Excipients Use In Soid Oral Formulation : A Review, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 4, 140-146. https://doi.org/10.5281/zenodo.10912711